Vericel Corporation (VCEL)
VCEL trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/887359/000162828026012013/0001628280-26-012013-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VCEL on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000887359 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | MI |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $276.3M |
| Net income | $16.5M |
| Operating income | $11.0M |
| Net margin | 6.0% |
| Operating margin | 4.0% |
| Revenue growth | +16.5% |
| Cash | $100.1M |
| Total assets | $488.0M |
| P/E (computed) | 177.6× |
| P/S (computed) | 10.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $133.5M cash; operating cash flow $16.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 51,029,770 (2026-10-29); 50,574,026 a year earlier; 47,724,543 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $7.7M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $85.4M | $14.2M | $17.7M | $133.5M | No debt tags | $324.2M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $77.5M | $2.2M | $16.2M | $125.4M | No debt tags | $306.3M | 10-Q 2026-07-30 |
| Q1 2026 2026-03-31 | $68.4M | -$6.3M | $16.4M | $109.3M | No debt tags | $292.1M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $92.9M | $23.2M | $15.0M | $100.1M | No debt tags | $276.3M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $67.5M | $5.1M | $22.1M | $100.4M | No debt tags | $258.7M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $63.2M | -$553K | $8.2M | $80.5M | No debt tags | $249.1M | 10-Q 2026-07-30 |
| Q1 2025 2025-03-31 | $52.6M | -$11.2M | $6.6M | $73.5M | No debt tags | $238.5M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $75.4M | $19.8M | $22.2M | $74.5M | No debt tags | $237.2M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-08-16 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-19 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.3% |
| 1 month | +41.3% |
| 3 months | +27.9% |
| Year to date | +58.2% |
| 1 year | +43.0% |
| From 52-week high | -4.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| TARS | Tarsus Pharmaceuticals Inc. | $78.68 | -1.99% | $3.9B |
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| BEAM | Beam Therapeutics Inc. | $20.94 | -8.28% | $2.2B |
| REPL | Replimune Group Inc. | $21.41 | -2.19% | $2.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier